1700.91 -4.64 -0.27%
Takeda Pharmaceutical Co, Japan's largest drugmaker, is in talks with Indian generic drugmakers Cipla and Lupin about buying one of the companies' pharmaceutical businesses.
Takeda Pharmaceutical Co, Japan's largest drugmaker, is in talks with Indian generic drugmakers Cipla and Lupin about buying one of the companies' pharmaceutical businesses, a financial paper reported on Wednesday.
Takeda, which has said it wants to expand in India, one of the world's fastest growing drug markets, has held preliminary talks with Cipla, while talks with Lupin have progressed beyond the initial stage, the newspaper said citing people with direct knowledge of the development.
Japanese drugmakers, hampered by rising hurdles to develop next-generation blockbuster products, have been active in global acquisitions, seeking to beef up their product pipelines.
A Takeda spokeswoman declined to comment on the report. A Cipla spokeswoman said, "We would like to clarify that these reports are baseless and untrue and is categorically denied."
A representative for Lupin could not immediately be reached by Reuters. The report said a Lupin official declined to comment.
Cipla is known for selling low-cost generic versions of anti-retroviral drugs used to fight HIV/AIDS. Lupin is a major producer of generic drugs.
The newspaper report said Takeda was interested in buying Lupin's domestic formulations business as well as its research facility, but its founders were not willing to sell the research unit.
Emerging markets are set to become the main driver for the global pharmaceuticals industry as patents run out on many top drugs and sales in Western markets stall, but acquisitions in those economies have not always come easy.
In 2009, Daiichi Sankyo, Japan's No.3 drugmaker, took majority control of Indian generic drug maker Ranbaxy Laboratories for USD 4.6 billion, but later saw profits fall at the unit following a US ban on some Ranbaxy products amid allegations of falsified data.
In a move to lift its presence in emerging markets, Takeda bought drugmaker Nycomed, which is well-placed in Russia and Brazil and owns a majority stake in a Chinese firm, for USD 13.7 billion.
At a news conference announcing the deal in May, Chief Executive Yasuchika Hasegawa said the Japan firm was open to further acquisitions.
In 2008, Takeda purchased US cancer specialist Millennium Pharmaceuticals for USD 8.8 billion in 2008. Other Japanese drugmakers have also been active in overseas acquisitions.
In recent years, Astellas Pharma bought OSI Pharma for USD 4 billion and Eisai purchased MGI Pharma for USD 3.9 billion to boost their cancer drug pipelines.
Shares in Takeda ended at 3,625 yen on Tuesday, down 0.7% versus an 1.1% fall in the benchmark Nikkei stock average.
Cipla stock price
On April 17, 2014, Cipla closed at Rs 400.60, up Rs 3.80, or 0.96 percent. The 52-week high of the share was Rs 450.00 and the 52-week low was Rs 364.05.
The company's trailing 12-month (TTM) EPS was at Rs 17.18 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 23.32. The latest book value of the company is Rs 110.47 per share. At current value, the price-to-book value of the company is 3.63.
READ MORE ON Takeda Pharmaceutical, Cipla, Lupin, pharmaceutical business, product pipelines, anti-retroviral drugs, HIV/AIDS, domestic formulations business, Daiichi Sankyo, Ranbaxy Laboratories, cancer drug
Set email alert for
ADS BY GOOGLE
1700.91 -4.64 -0.27%
video of the day
Chandra says satisfied with TCS' FY14, FY15 to be better